利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.022 秒)

    ADAPTIVE DATA TRANSMITTER HAVING REWRITEABLE NON-VOLATILE STORAGE
    1.
    发明申请
    ADAPTIVE DATA TRANSMITTER HAVING REWRITEABLE NON-VOLATILE STORAGE 失效
    具有可逆非易失性存储的自适应数据传输器

    公开(公告)号：US20050111567A1

    公开(公告)日：2005-05-26

    申请号：US10707199

    申请日：2003-11-26

    申请人： Louis Hsu ,  Brian Ji ,  William Washburn

    发明人： Louis Hsu ,  Brian Ji ,  William Washburn

    IPC分类号： H03H21/00 ,  H04L25/03 ,  H04L27/04

    CPC分类号： H04L25/03343 ,  H03H21/0012

    摘要： A data transmitter and transmitting method are provided in which an adaptive finite impulse response (FIR) driver has a plurality of taps to which coefficients having updateable values are applied. The FIR driver has a transfer function between an input stream of data bits and an output stream of data bits such that each data bit output from the FIR driver has an amplitude adjusted as a function of the values of a plurality of data bits of the input stream, and the values of the coefficients. The data transmitter includes a rewriteable non-volatile storage, operable to be rewritten with control information representing the values of the coefficients updated during operation of the FIR driver.

    摘要翻译： 提供了一种数据发送器和发送方法，其中自适应有限脉冲响应（FIR）驱动器具有应用具有可更新值的系数的多个抽头。 FIR驱动器在数据位的输入流和数据位的输出流之间具有传递函数，使得从FIR驱动器输出的每个数据位的幅度根据输入的多个数据位的值而被调整 流，以及系数的值。 数据发送器包括可重写的非易失性存储器，可操作以用表示在FIR驱动器的操作期间更新的系数的值的控制信息进行重写。

    2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    3.
    发明申请
    2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors 有权
    2-氨基-3-官能化的四氢化萘衍生物和相关的糖原磷酸化酶抑制剂

    公开(公告)号：US20060111413A1

    公开(公告)日：2006-05-25

    申请号：US11273167

    申请日：2005-11-14

    申请人： Philip Sher ,  Gang Wu ,  Wei Meng ,  Alexandra Nirschl ,  William Washburn ,  Terry Stouch

    发明人： Philip Sher ,  Gang Wu ,  Wei Meng ,  Alexandra Nirschl ,  William Washburn ,  Terry Stouch

    IPC分类号： A61K31/4184 ,  A61K31/407 ,  C07D498/02 ,  C07D407/02

    CPC分类号： C07D209/42 ,  C07D235/24 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D491/04 ,  C07D493/08 ,  C07D495/04

    摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, X, Y and Z are defined herein.

    摘要翻译： 提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管 与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件 包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。 这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1，R 2，X，Y和Z在本文中定义。

    2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    4.
    发明申请
    2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors 有权
    2-氨基-4-官能化的四氢化萘衍生物和相关的糖原磷酸化酶抑制剂

    公开(公告)号：US20060111338A1

    公开(公告)日：2006-05-25

    申请号：US11272845

    申请日：2005-11-14

    申请人： Philip Sher ,  Alexandra Nirschl ,  Wei Meng ,  William Washburn

    发明人： Philip Sher ,  Alexandra Nirschl ,  Wei Meng ,  William Washburn

    IPC分类号： A61K31/4709 ,  A61K31/4184 ,  A61K31/407 ,  C07D403/14

    CPC分类号： C07D401/12 ,  C07D209/42 ,  C07D403/12

    摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, X and Z are defined herein.

    摘要翻译： 提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管 与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件 包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。 这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1，R 2，X和Z在本文中定义。

    SHIFTER APPARATUS WITH ADJUSTABLE SHIFT STICK LENGTH AND TENSION SELECTION FEATURES
    5.
    发明申请
    SHIFTER APPARATUS WITH ADJUSTABLE SHIFT STICK LENGTH AND TENSION SELECTION FEATURES 审中-公开
    具有可调节移位长度和张力选择功能的更换装置

    公开(公告)号：US20130036850A1

    公开(公告)日：2013-02-14

    申请号：US13584766

    申请日：2012-08-13

    申请人： Colin J. Corey ,  William Washburn ,  Craig Corey

    发明人： Colin J. Corey ,  William Washburn ,  Craig Corey

    IPC分类号： B60K20/02

    CPC分类号： B60K20/02 ,  B60K20/04 ,  Y10T74/20018 ,  Y10T74/20159 ,  Y10T74/20171

    摘要： A remote shifter apparatus for use in a manual transmission equipped vehicle includes a base, a length adjustable shift stick, a transmission shift lever engaging fastener and a linkage directly coupling the stick to the fastener to translate shift stick movement to the transmission lever. The shift stick is free to rotate laterally and longitudinally relative to the vehicle drive axis and about a ball joint to cause the transmission lever to be moved through its full range of motion for each gear. A mechanism is provided for enabling adjustment of the length of the shift stick to accommodate selective variations in throw length. The ball joint frictional relationship between shift stick and base is also selectively adjustable to provide a customizable shift feel to improve feedback to the driver.

    摘要翻译： 用于手动变速器车辆中的遥控换档装置包括基座，长度可调换档杆，变速杆换向杆接合紧固件和将杆直接连接到紧固件上以将换档杆移动到传动杆的连杆。 换档杆可相对于车辆驱动轴线和球形接头横向和纵向自由地旋转，以使传动杆通过其每个档位的全部运动范围。 提供了一种用于能够调整换档杆的长度以适应投掷长度的选择性变化的机构。 变速杆和底座之间的球关节摩擦关系也可选择性地调节，以提供可定制的换档感觉，以改善对驾驶员的反馈。

    Non-basic melanin concentrating hormone receptor-1 antagonists
    7.
    发明申请
    Non-basic melanin concentrating hormone receptor-1 antagonists 有权

    公开(公告)号：US20070093508A1

    公开(公告)日：2007-04-26

    申请号：US11586147

    申请日：2006-10-25

    申请人： Saleem Ahmad ,  Khehyong Ngu ,  William Washburn

    发明人： Saleem Ahmad ,  Khehyong Ngu ,  William Washburn

    IPC分类号： A61K31/519 ,  C07D498/02

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
    8.
    发明申请
    2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors 有权
    2-氨基萘衍生物和相关糖原磷酸化酶抑制剂

    公开(公告)号：US20060111415A1

    公开(公告)日：2006-05-25

    申请号：US11273479

    申请日：2005-11-14

    申请人： Wei Meng ,  Philip Sher ,  Bruce Ellsworth ,  William Washburn

    发明人： Wei Meng ,  Philip Sher ,  Bruce Ellsworth ,  William Washburn

    IPC分类号： A61K31/4184 ,  A61K31/407 ,  C07D498/02 ,  C07D235/18

    CPC分类号： C07D235/24 ,  C07D209/42 ,  C07D491/04 ,  C07D495/04

    摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1 and R2 are defined herein.

    摘要翻译： 提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管 与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件 包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。 这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1和R 2 2定义在本文中。

    Non-basic melanin concentrating hormone receptor-1 antagonists
    10.
    发明申请
    Non-basic melanin concentrating hormone receptor-1 antagonists 有权
    非基本黑色素浓缩激素受体-1拮抗剂

    公开(公告)号：US20070093509A1

    公开(公告)日：2007-04-26

    申请号：US11586255

    申请日：2006-10-25

    申请人： William Washburn ,  Mark Manfredi ,  Jeffrey Robi ,  Andres Hernandez

    发明人： William Washburn ,  Mark Manfredi ,  Jeffrey Robi ,  Andres Hernandez

    IPC分类号： A61K31/519 ,  C07D498/02 ,  A61K31/675

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。